Metastases and Variant Histology in Urothelial Cancer
September 14th 2021Thomas Powles, MBBS, MRCP, MD, leads the discussion on selecting chemotherapy vs immune checkpoint inhibitors in the adjuvant setting for a patient who has metastases in urothelial carcinoma as well as approaching therapy for variant histology.
Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW
September 10th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.
Clinical Impact of Biomarkers on Advanced Urothelial Cancer
September 7th 2021Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, comment on the role of biomarker testing and its impact on the patient selection and approach to treatment for advanced urothelial carcinoma.